Rivastigmine Tartrate Patent Expiration

Rivastigmine Tartrate is Used for managing symptoms of Alzheimer's dementia. It was first introduced by Novartis Pharmaceuticals Corp in its drug Exelon on Apr 21, 2000. 11 different companies have introduced drugs containing Rivastigmine Tartrate.


Rivastigmine Tartrate Patents

Given below is the list of patents protecting Rivastigmine Tartrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Exelon US5602176 Phenyl carbamate Feb 11, 2014

(Expired)

Novartis
Exelon US4948807 Phenyl carbamates Aug 14, 2012

(Expired)

Novartis



Rivastigmine Tartrate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Rivastigmine Tartrate Generic API Manufacturers

Several generic applications have been filed for Rivastigmine Tartrate. The first generic version for Rivastigmine Tartrate was by Sun Pharmaceutical Industries Ltd and was approved on Oct 22, 2007. And the latest generic version is by Chartwell Rx Sciences Llc and was approved on Sep 28, 2017.

Given below is the list of companies who have filed for Rivastigmine Tartrate generic, along with the locations of their manufacturing plants worldwide.